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INTRODUCTION 
 
The immune system is a fascinating and complex system of molecules, cells and 
organs that has evolved to protect the body against invading pathogens, such as 
bacteria, virus and parasites. The immune responses that are initiated upon pathogen 
entry are divided into innate immunity and adaptive immunity. The innate immune 
response is the first line of defense, and is an early non-specific response by white 
blood cells, or leukocytes, that recognize non-self entities common to microbes. 
Innate responses include recruitment of immune cells to the site of infection for 
pathogen removal, inflammation, and activation of the complement cascade. The 
innate response is also responsible for activating the adaptive response, initiated by 
professional antigen presenting cells (APC). These cells engulf and process pathogens 
and subsequently present pathogen-derived fragments on the cell surface. T 
lymphocytes (T cells) of the adaptive immune system recognize the fragment by 
means of their antigen specific T-cell receptors (TCR). Upon recognition, these 
lymphocytes get activated and evolve into effector cells, resulting in a pathogen 
specific response much more potent than the initial innate response. At this stage the 
innate and adaptive response synergize to clear the infection by effector T cells killing 
pathogen infected cells directly, or by cytokine production which stimulates other 
cells of the immune system, like macrophages and B lymphocytes (B cells). The B 
cell, another cell of the adaptive immune system, has surface expressed 
immunoglobulin (Ig) as antigen specific B-cell receptors (BCR). Upon activation, 
these cells secrete soluble versions of the BCR, called antibodies, which are necessary 
to combat the pathogen. After the pathogen has been cleared, effector cells are 
removed except for a subset of the lymphocytes, termed memory cells, which allow 
for a quicker response to a subsequent infection of the same pathogen. 
 
The APCs present protein fragments, or peptides, to circulating T lymphocytes via 
certain proteins of the major histocompatibility complex (MHC) to. These surface 
expressed proteins, termed human leukocyte antigen (HLA) in humans, are divided 
into two classes. MHC class I molecules (MHC I) are expressed by all nucleated cells. 
These molecules generally present self or foreign peptides from the interior of the 
cells to cytotoxic CD8+ T cells. The MHC class II molecules (MHC II) are selectively 
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expressed by epithelial cells in the thymus, and professional APCs, including 
dendritic cells, macrophages and B cells. These molecules mainly present 
endocytosed proteins.  
 
The MHC molecules are of great importance for the body’s ability to detect an 
intrusion of foreign entities and initiate a response towards these pathogens. However, 
these molecules may also elicit undesirable immune responses, exemplified by MHC 
presentation of self peptides that may lead to autoimmune disease. A common feature 
of many autoimmune diseases, like rheumatoid arthritis, type 1 diabetes and systemic 
lupus erythematosus, is the lacking identity of the disease-causing antigen, which 
makes studying these diseases cumbersome and difficult. Celiac disease (CD), 
however, has a known antigen in the form of gluten, which becomes more 
immunogenic after transglutaminase 2 (TG2) modification. The chronic intestinal 
inflammation, a hallmark of this disease, is the result of the activation of T cells 
recognizing gluten peptides presented by HLA-DQ2.5 (DQ2.5) or HLA-DQ8 (DQ8) 
molecules. Much is known about the role of particularly DQ2.5 to CD. However, this 
molecule is associated with numerous other autoimmune diseases as well, indicating a 
possible uniqueness of this molecule. This thesis focuses on the underlying 
mechanism for the selective celiac disease association with DQ2.5, but also the 
detection of gluten specific T cells in peripheral blood, by means of soluble 
recombinant MHC molecules. 
 
MHC II molecules 
 
MHC I and MHC II are both important molecules in the immune response. However, 
as DQ2.5 is a class II molecule, I will focus on this class of MHC in this introduction. 
The MHC II molecules are membrane bound heterodimeric glycoproteins encoded in 
a gene complex on the short arm of chromosome 6 (6p21.3), encompassing ~3.6Mb. 
Three isoforms of peptide binding MHC II exist in humans, termed HLA-DP, -DQ, 
and -DR. These molecules have differential cellular expression levels, where DQ and 
DP show approximately ten-fold and hundred-fold lower expressions compared to 
DR, respectively. All three isoforms consist of an -chain of 35kDa, and a -chain of 
28kDa.With the exception of the locus encoding for the -chain of DR, termed 
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DRA1, the genes encoding for DRB1, DQA1, DQB1, DPA1 and DPB1 are highly 
polymorphic. Each chain consists the membrane proximal domain, the membrane 
distal domain, a transmembrane domain, and a short cytoplasmic tail. The membrane 
distal domain is what constitutes the peptide binding groove, with a -sheet providing 
the floor and two -helixes forming the walls of the groove. This is based on the 
crystal structure of a diverse set of MHC molecules, pioneered by Brown et al 1. The 
MHC II molecule has an open ended groove, meaning that even though the groove 
itself accompany a core of 9 residues, longer peptides (10-34 residues) are allowed to 
bind with ends protruding from the groove2. The crystal structure also revealed two 
main principles of peptide binding: (1) Hydrogen bonding between MHC backbone or 
conserved residues and the main chain carbonyl oxygen and amide nitrogen groups of 
the peptide, and (2) “pocket-anchor” interactions, where the side chains of peptides 
interact with polymorphic MHC residues3-5. The former principle provides a universal 
affinity for peptides of variable sequence, while the latter principle determines the 
differential peptide specificities for the different MHC molecules. In addition to the 
conserved hydrogen bonding network, there are also MHC specific hydrogen bonding 
to the peptide, which further determines the binding affinity. Upon binding to the 
MHC molecule, the peptide conforms to a type II polyproline (PPII) helix4,6,7. This 
allows for extensive interaction of the peptide side chains with both the MHC pockets 
(peptide residues in position P1, P4, P6, P7 and P9) and the TCR of the T cell 
(residues in P2, P5 and P8) (Fig. 1). 
 
 
Figure 1: Schematic representation of the conserved hydrogen bonding involved in MHC II peptide 
binding. MHC II interaction with peptides (in black) includes accommodation of peptide side chains 
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(denoted “P”) in MHC II “pockets” (in grey), and conserved hydrogen bonding (red dashed lines) 
between peptide backbone and MHC II main chain or conserved residues. Residues of the MHC II -
chain and -chain are represented in blue and green, respectively. The peptide side chains are 
numbered according to their position relative to MHC II pocket 1. The peptide has not been depicted in 
a PPII helix for simplicity. The figure is based on HLA-DR1, and has been modified from 8. 
 
HLA nomenclature 
 
Human leukocyte antigens were first described in the mid 1950’s, through the 
discovery of antibodies recognizing donor leukocyte antigens in blood transfusion 
recipients. During the next two decades the vast increase of identified leukocyte 
antigens revealed the requirement for a standardized nomenclature. This was resolved 
over a series of international histocompatibility workshops, and the term HLA was 
coined in 19759. As of 1999, more than 220 genes have been characterized in the 
HLA region10, and a vast number of polymorphisms have been described11. The 
resulting HLA nomenclature is therefore complex and is based both on the original 
method of serotyping, but also genotyping, which better distinguishes the 
polymorphisms in HLA. The limitations associated with serotyping can be 
exemplified with DQ2 (Fig. 2). This molecule was identified by using an antibody 
that recognizes the -chain (DQB1*02). However, because this -chain can dimerize 
with two different -chains (DQA1*0501 and DQA1*0201), genotyping is required to 
discriminate between the two resulting forms of DQ2. The extended term DQ2.2 and 
DQ2.5 was therefore introduced for these two molecules, where the last digit refers to 
the -chain of the allele12.  
 
 
Figure 2: HLA nomenclature based on serotype vs. genotype. The DQ2 
serotype does not distinguish between the two DQ2-variants DQ2.2 and 
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DQ2.5 due to antibody recognition of the DQB1*02 molecule (green arrow). 
The genotyping, however, reveals two different DQ2 alleles based on their 
different -chains (DQA1*0501 for DQ2.5 and DQA1*0201 for DQ2.2). 
  
The naming of an HLA molecule is here exemplified by the HLA-DQA1*0501 
molecule of the DQ2.5 allele. The first part of the name, “HLA” specifies the gene 
region. The second part, DQA1, specifies the locus within this gene region, while the 
first two digits following the asterix, “05”, refers to the allele group, and is often 
similar to the serotype. The following two digits, “01”, refer to the specific allele 
within the allele group. Variations within the gene that do not cause amino acid 
changes are denoted by additional following digits13. 
 
Antigen processing and presentation 
 
MHC II molecules assemble in the endoplasmic reticulum (ER) with the help of the 
chaperone molecule Invariant chain (Ii). The resulting complex forms a nonamer 
consisting of three molecules of each -, - and Ii-chains. The Ii serves three major 
purposes: (1) Assuring assembly and proper folding of the MHC II molecules14, (2) 
preventing premature loading of peptides located in the ER by occupying the antigen 
binding groove with a short sequence termed Class II associated Ii peptide (CLIP)15, 
and (3) translocation of the nonameric Ii complex out of the ER, via the trans-
Golgi-apparatus, and to the multivesicular MHC class II containing compartment 
(MIIC), which is a specialized late endosomal compartment16,17. The translocation is 
mediated by transport signals located in the N-terminal cytoplasmic tail of the Ii 
molecule16,17. Due to alternative initiation of translation, Ii has several N-terminally 
truncated isoforms, which consequently affects the transport signaling. The actual 
route of transport therefore depends on the isoform of the Ii that chaperones the MHC 
II molecule, causing the Ii nonamer to either directly translocate to the MIIC18,19, or 
use an indirect pathway by way of the plasma membrane and/or entering the early 
endosomes prior to arriving at the MIIC20,21. The simultaneous presence of all these 
pathways have been suggested to be of advantage to the cell by ensuring access to 
potential foreign antigens present in many different intracellular compartments20,22. 
During transition from the early endosomes to the MIIC the compartments gradually 
become more acidic, and degradation of Ii by proteases of the aspartyl and cathepsin 
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family causes the Ii nonameric complex to disassemble, leaving CLIP in the 
peptide binding groove. The MHC II-CLIP complex is now available for peptide 
antigen exchange. 
 
Internalized antigens are trafficked through the endocytic pathway to the MIIC. They 
are processed by the same protease machinery as Ii, following an initial denaturing by 
the enzyme GILT (interferon- (IFN-) inducible thiol reductase)23, making the 
resulting peptide fragments available for MHC II binding. However, the binding of 
antigenic peptides to MHC II is dependent on the release of CLIP, a process shown to 
be accelerated by the molecule HLA-DM24-26. This non-classical MHC II molecule 
interacts with the MHC II-CLIP complex which results in conformational changes 
that causes destabilization and subsequent release of CLIP. This peptide receptive 
state of the MHC II molecule, is maintained by DM until a peptide with sufficient 
affinity is bound, upon which the DM-MHC interaction ceases25,27. The MHC II-
peptide complex is then transported to the cell surface, by a still poorly understood 
mechanism, for the recognition of CD4+ T cells of appropriate specificity. The entire 
pathway is depicted in Figure 3.  
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Figure 3  Antigen processing pathway. MHC II molecules assemble in the ER with the chaperone Ii in 
a nonamer complex. The nonamer translocates to the MIIC via three possible pathways: 1) Directly to 
the MIIC; 2) via the cell surface to the early endosomes (EE) prior to MIIC entry; or 3) directly to EE 
prior to MIIC entry. Once in the MIIC, proteases digest Ii, leaving CLIP in the binding groove. 
Internalized antigen is degraded by the same protease machinery, and is ready for MHC II binding. 
MHC II-CLIP complex interacts with HLA-DM, which removes CLIP and allows for internalized 
degraded peptide antigens to bind. The MHC II-peptide complex migrates to the cell surface for 
recognition by CD4+ T cells. 
 
MHC II presentation of peptides is not, however, critically dependent on antigen 
internalization and processing. Surface exchange of antigens have been demonstrated 
for peptides of various lengths up to 39 amino acids 28-30, and even larger proteins 
have been reported to be processing independent31. This mechanism is DM 
independent and requires the presence of low affinity MHC II-peptide complexes for 
efficient exchange.   
 
Accessory molecules in antigen presentation 
Invariant chain 
Ii is a type II transmembrane protein expressed mainly by APCs, but also by other cell 
types during inflammation. Ii comes in different N-terminal truncated isoforms, 
termed p33, p35, p41 and p43, based on their molecular weight32. The isoforms are 
the result of alternative translational initiation, or alternative splicing and come in a 
major form, termed p33 (33kDa), and a minor form, termed p35 (35kDa). The p41 
(41kDa) and p43 (43kDa) isoforms have an additional internal cystein-rich exon, but 
are otherwise identical to the shorter variants. All isoforms contain di-leucine 
transport motifs causing endosome translocation, while the p35/p43 variants have an 
additional di-arginine motif causing ER retention in the absence of MHC II. In 
addition, studies show that the p35/p43 isoforms are directly transported to the MIIC, 
while the p33/p41 isoforms are responsible for the cell surface/early endosome 
targeting21. Recently, a distinct new role for p41 as a cathepsin inhibitor have been 
suggested33. 
 
The Ii molecule is able to associate with a divergent set of MHC molecules by not 
only accommodating CLIP in the binding groove, but also through association with 
13 
regions outside the groove with sequences both C- and N-terminally of the CLIP 
sequence34-36. As the nonameric complex moves through the endocytic pathway, a 
pool of proteases sequentially cleave the Ii in a C-terminal to N-terminal direction, 
revealing size intermediates termed p22 (LIP) and p10 (SLIP)37. The additional 
enzymes involved in these processes are not known and appear to be redundant. 
However, the release of CLIP from the transmembrane and cytosolic domains of the Ii 
is less redundant and attributed to the enzymes cathepsin S or L, depending on the cell 
type.  
 
The importance of Ii is demonstrated in knock out studies done in mice, showing 
faulty assembly and folding, and retention of the MHC II in the ER, which ultimately 
results in reduced amounts of MHC II on the cell surface38,39. The absence of Ii would 
therefore reduce the effectiveness of antigen presentation, and culminate in a decrease 
in the CD4+ T cell number and diversity40. Ii has also been implicated in other cellular 
functions. The remnant N-terminal fragment after cathepsin S degradation of SLIP 
has been associated with B cell differentiation, through its implication in the 
activation of the transcription factor NF-B41. Another recent study, by Faure-André 
et al, revealed a role for Ii in the migrational control of DC, suggested to increase the 
ability of the DC to encounter and process antigens in the tissues42. Ii has also been 
implicated in the intracellular trafficking of the FcRn receptor43. The function and 
relevance of this association is, however, not understood. 
 
HLA-DM and HLA-DO 
HLA-DM was discovered in the early nineties when E. Mellins, D. Pious and 
colleagues studied cells with antigen processing defects44. The defect was later linked 
to a mutation in the MHC region, causing loss of HLA-DM expression45. However, 
the molecule is not directly linked to the presentation of the peptides, as this non-
classical MHC II molecule is unable to bind peptides due to a closed binding 
groove46. Instead, it transiently interacts with MHC II molecules, allowing the 
exchange of CLIP for antigenic peptides. Studies involving the HLA-DR1 allele 
demonstrate that the lateral face of DM interacts with the side of the DR1 molecule 
that accompanies the N-terminus of the bound peptide47,48. The proposed mechanism 
of peptide release involves a conformational change of the MHC II molecule due to 
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the DM interaction. The resulting “floppy” conformation is caused by H-bond 
disruption between MHC residues and peptide backbone, shown to be located around 
pocket 1 of the MHC II binding groove (residues 51-53 and 81)8,46,47,49-51. Once 
CLIP is removed, HLA-DM functions as a peptide editor by keeping the MHC 
molecule in a peptide receptive conformation until a peptide of sufficient affinity 
binds52,53. Lower affinity peptides will have the same faith as that of CLIP. This 
system of selection ensures that the cell presents a smaller set of immunodominant 
peptides instead of a wide variety of peptides of moderate affinity.  
 
Studies in mice where the murine variant of HLA-DM (H2-M) was knocked out 
revealed an unaltered quantity of MHC II. However, the peptides presented were 
mainly CLIP peptides, thus demonstrating a severely hampered ability to display a 
variety of antigens. This results in an inefficient intrathymic positive selection of 
CD4+ T cells, revealing a slight decrease in quantity and greatly reduced diversity of 
T cells54,55. The intrathymic negative selection was also affected, as seen by the 
appearance of autoreactive T cells56. Another similar study has further demonstrated 
that mice lacking H-2M display a more promiscuous population of CD4+ T cells, 
recognizing numerous antigenic epitopes instead of a few immunodominant 
epitopes57.  
 
HLA-DO is another non-classical MHC class II molecule believed to have a closed 
binding groove due to its inability to bind peptides58. It is principally expressed in 
mature B cells59, but more recent studies also report its expression in primary mature 
dendritic cells60. HLA-DO is critically dependent on its interaction with HLA-DM, 
which ensures its assembly, stability, and eventual transport out of the ER61. Its 
effects on antigen presentation are mediated through this interaction by negatively 
regulating the activity of HLA-DM62,63, though one study also reports positive 
regulation64. The biological benefit of DO is unknown. One suggested effect of the 
inhibition of DM is a preference for the presentation of exogenous over endogenous 
antigens by MHC II65. This is attributed in part by the ability of DO to limit the 
activity of DM to that of the late endosomes, in a pH dependent manner66. This 
favours loading of peptides in MIIC, which, in the case of B cells, are enriched due to 
antigen specific BCR internalization. The DO:DM ratio has also been reported to be 
lower in the late endocytic pathway67. Mice knockout studies of the murine variant of 
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HLA-DO (H2-O) reveal a weakened ability to present foreign antigen, an impaired 
humoral immune response, and increased presence of autoimmune antibodies as the 
mice ages65. This supports the role of DO in maximizing the ability of the mature B 
cell or DC to favourably present exogenous over endogenous antigens. 
 
Professional antigen presenting cells 
 
All cells, except red blood cells, have the ability to present antigens on their surface 
by means of MHC molecules. However, APCs also present antigens by means of 
MHC II molecules, although a transient MHC II expression may occur in other cells 
as well. The APCs include dendritic cells, macrophages, and B cells. 
Dendritic cells 
The dendritic cell (DC), named for its characteristic cellular projections, was 
identified in 1973 by Steinman et al68. There are two distinct types of DCs, the 
myeolid DC and the plasmacytoid DC. The myeloid DC is the primary cell that 
activates naïve T cells, and is therefore of particular importance for the initiation of an 
immune response. Immature DCs survey the tissues in search for foreign entities, and 
undergo a process of maturation upon recognition/activation. The maturation process 
involves a down-regulation of antigen uptake, and up-regulation of antigen 
presentation, exemplified by a ten fold increase in MHC half-life69. This long half-
life, combined with the functional irreversibility of the bound antigen70, thus increases 
the capability of the DCs to activate T cells. The expression of chemokine receptor 
CCR7 is also induced, which enables the DC to migrate to the lymph node via the 
lymph71. Upon arrival, the DC encounter and activate antigen specific naïve T cells, 
which subsequently undergo maturation and proliferation72. 
 
The exact function of the other major subtype, the plasmacytoid DCs, is unclear, 
However, this cell has been associated with a large production of type I interferons in 
response to virus infection73. 
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Macrophages 
Macrophages are large mononuclear phagocytotic cells located in tissues. These 
leukocytes are important scavengers, removing necrotic and apoptotic material. 
However, they also play an important role in the immune system, contributing in 
innate immunity by engulfing and destroying encountered pathogens74. Upon 
pathogenic activation they assist the adaptive part of the immune system as APCs by 
upregulating antigen processing mechanisms and MHC II expression75. Unlike DCs, 
however, the activated macrophages do not migrate to the lymph nodes, but rather 
remain in the tissue for stimulation of tissue recruited mature T cells and mediate 
immune cell recruitment through cytokine secretion. 
B cells 
B cells differ from the other types of APCs in that they are mainly located in 
peripheral lymphoid organs in their naïve state. They are also less promiscuous, but 
more effective with regards to antigen internalization. The primary mechanism of 
antigen uptake is through the BCR, which specifically binds the antigen. Sufficient 
stimulation by BCR cross linking causes antigen internalization and subsequent up-
regulation of the antigen processing mechanisms76. However, complete activation of 
the B cell is dependent on T-cell interaction, implying that B cell activation of naïve T 
cells is limited, although possible76,77. Mature B cells secrete pathogen specific 
antibodies, which are of dire importance for the adaptive immune response because of 
the antibodies ability to opsonize and neutralize pathogens. 
 
T-cell activation 
 
T cells originate from the bone marrow, but migrate to the thymus where they 
undergo maturation and selection. This involves the surface expression of a functional 
 heterodimeric TCR and the subsequent positive and negative selection based on 
TCR recognition of self-peptides presented on MHC molecules. Upon maturation, the 
naïve T cells are allowed to enter the blood stream and circulate through the 
secondary lymphoid organs in search for antigen presented by APC78. 
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There are two subsets of T cells, CD4+ and CD8+, named by their associated co-
receptor molecules. CD4+ T cells are activated by pathogenic antigen presented by 
APCs expressing MHC II, and the resulting effector cells are involved in regulating 
the humoral and cellular immune system. CD8+ T cells, on the other hand, are 
activated by MHC I-antigen complex and their effector functions include the 
recognition and killing of pathogen infected cells. The activation of naïve T cells 
consists of two major signals, 1) the peptide MHC recognition by the TCR, and 2) the 
co-stimulatory molecule CD28 interacting with B7 molecules on the DC79. The 
combined signal results in activation and maturation of the naïve T cell into effector 
or memory T cells. The effector cells have a direct role in the ongoing immune 
response and migrate to the site of infection, where they are activated upon 
appropriate antigenic stimulation. The memory cells, on the other hand, are quiescent 
until a subsequent infection occurs, by which a faster response may be elicited.  
 
The migration of T cells from the peripheral lymphoid organs to the site of the 
infection, also called “homing”, is mediated by the expression of a combination of 
adhesion and chemoattractant receptors80. These receptors allow the cells to attach to 
the capillary wall at the site of infection and subsequently enter the tissue through a 
process called diapedesis. 
 
 
Autoimmunity 
 
The development and maturation of lymphocytes involves a variety of selection 
processes to ensure that the resulting diverse repertoire can respond to all encountered 
pathogens. There is a pitfall associated with this powerful process, because with 
higher diversity comes higher frequency of self-reactive lymphocytes. These self-
reactive lymphocytes, however, are normally eliminated due to several tolerogenic 
mechanisms, the primary mechanism being negative selection in the bone marrow or 
thymus, termed central tolerance. The intrathymic elimination of autoreactive T cells 
is the most stringent process and is critically dependent on T cell exposure to all 
potential self antigens. This is made possible by the expression of the transcription 
factor Autoimmune Regulator gene (AIRE)81,82. AIRE, expressed by stromal cells in 
the thymus, allows for the thymic expression of, and therefore also T-cell tolerance 
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towards tissue specific antigens that are normally restricted to specialized peripheral 
organs83. The negative selection is largely assisted by thymic DCs, which are thought 
to acquire tissue specific antigen from the stromal cells83. As some autoreactive T 
cells do escape this primary selection, there are also lymphoid and non-lymphoid 
associated peripheral tolerogenic mechanisms that can eliminate these mature T cells 
as well. The system is not perfect, however, and under certain conditions, like that of 
an infection, autoreactive lymphocytes may emerge84. This may lead to 
autoimmunity, caused by an abnormal B- and T-cell recognition of self antigens, 
leading to autoantibody production by B cells and possibly autoimmune disease.  
 
The involvement of autoreactive T (and B) cells in autoimmune disease implicates a 
role of HLA in the disease mechanism, due to the requirement of peptide presentation. 
Coincidentally, most, if not all autoimmune diseases are associated with one or more 
HLA alleles85. A list of autoimmune diseases and their HLA association is given in 
table 1.  
Table 1: Examples of HLA-associated autoimmune diseases 
 
Antigen frequencies in a Norwegian population. (RR): Relative risk, i.e. how many 
times more frequent the disease is in those having the corresponding HLA molecule 
compared to those lacking it. Not included is the RR of DQ2.5 with type 1 diabetes. 
Table from Thorsby, et al 11. 
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The disease association can either confer susceptibility for, or protection from the 
disease. In the case of type 1 diabetes, several alleles confer susceptibility for the 
disease DQ2, DQ8, DR4.1 and DR4.5 confer susceptibility, while DQ6 and DR4.3 do 
not, as reviewed in86. Although the HLA association is known, the underlying 
molecular mechanism for this association is often elusive. This can be contributed to 
the fact that these diseases are commonly polygenic diseases that are also influenced 
by environmental factors86. Another complicating factor is the frequently unknown 
autoantigen(s), which makes the studying of these diseases more difficult. As 
previously mentioned, CD is an autoimmune disease with a strong linkage to HLA 
and with a known antigen, gluten, and the following section will describe this disease 
in more detail. 
 
Celiac disease 
History and clinical aspects 
Celiac disease (CD) is a complex inflammatory disorder of the small intestine caused 
by an inappropriate immune response to dietary proteins in wheat, barley and rye. The 
disease was first described by S. Gee in 188887, and later refined in the 1950s by W. 
Dicke who demonstrated that a factor in wheat, later defined as gluten, attributed to 
the onset of the disease88. 
 
The gluten sensitive enteropathy, as a result of the chronic inflammation, is 
characterized by villous atrophy, crypt hyperplasia, and increased infiltration of 
lymphocytes in the epithelium and lamina propria89. The clinical symptoms of the 
disease include typical intestinal features, such as chronic diarrhea, failure to thrive 
and distended abdomen, but also atypical extraintestinal features such as osteoporosis, 
anemia and ataxia90. However, the disease can also be asymptomatic91. Except in the 
case of refractory celiac disease89,92, the enteropathy and symptoms disappear upon 
removal of the precipitating grain from the diet. In the absence of treatment, however, 
the disease may lead to gastrointestinal lymphomas, the development of associated 
autoimmune diseases90, and death93. 
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The diagnostics of CD include serological testing and intestinal biopsy analysis. The 
former detects for the presence of disease associated antibodies in blood having 
specificity for gluten, endomysium and for TG294,95. The IgA autoantibodies for TG2 
has a very high disease sensitivity and specificity (95-99%)96,97 and is most commonly 
applied. However, upon a positive serological screening, the definite diagnosis is done 
by performing morphology analysis on intestinal biopsies. The only safe and effective 
treatment of celiac disease to date is the adherence to a life-long gluten free diet. 
 
Genetic factors 
The prevalence for CD is reported to be ~1% in the western population98, and there is 
a distinct familial tendency of disease development indicative of a genetic component 
in addition to the environmental factor. This is supported by the high rate of pairwise 
concurrence (75%) found in monozygotic twins, compared to the lower rate observed 
for dizygotic twins and in first degree relatives (20% and 10%, respectively)99. The 
primary genetic component in CD is HLA, accounting for about 50% of the genetic 
predisposition100. More than 90% of the patients express DQ2.5 
(DQA1*0501/DQB1*0201)101, while most of the remaining express DQ8 
(DQA1*0301/DQB1*0302)102. The DQ2.5 allele can either be expressed in cis ( and 
-chain located on the same chromosome), as in the DR3-DQ2 haplotype, or in trans, 
( and  chains located on separate chromosomes) as in the case of DR7-DQ2 and 
DR5-DQ7 heterozygotes. A minority of the non-DQ2.5 and -DQ8 CD patients 
express the DQ2.2 (DQA1*0201/DQB1*0202) allele of the DR7-DQ2 haplotype103.  
 
DR3-DQ2 is a common haplotype expressed by 20-30% of the normal population, 
suggesting the involvement of additional genetic components. A recent genome wide 
association study determined the 4q27 region, containing IL-2 and IL-21 as (non-
HLA) genes predisposing for CD104. There was also a weak association with the 
previously reported ICOS-CTLA4 region105, while the previously indicated CD 
susceptibility gene MYO9B106, did not show association. A follow up study found 
seven new chromosomal regions containing genes involved in immune responses107, 
which have been replicated108. Together with the 4q27 region, these eight regions are 
estimated to account for 3-4% of the CD heritability, which emphasizes the 
polygeneity. 
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HLA-DQ2 and gluten 
Two major contributors of celiac disease are the genetic component DQ2.5 and the 
environmental component gluten. These factors have a unique interplay based on 
several aspects, which causes activation of an immune response. Gluten is the major 
storage protein in wheat, and can be divided into two major groups, glutenins and 
gliadins, based on their alcohol solubility. These proteins are unusually high in their 
proline and glutamine content109. Two features of gluten contribute to the unique 
interplay with DQ2.5. First, due to their high proline content, they are highly resistant 
to gastrointestinal enzymatic degradation, allowing for larger peptide fragments to 
pass through the epithelium into the lamina propria. One such peptide was found 
through mimicking intraluminal enzymatic conditions, which revealed a proline rich 
and highly stimulatory fragment of 33 residues110. Second, the combination of high 
proline and glutamine content also makes these peptide fragments efficient targets for 
the enzyme TG2111-113. This multifunctional enzyme modifies neutral glutamines to 
negatively charged glutamic acids through a process called deamidation. 
 
The resulting proline-rich deamidated gluten peptides are well suited for binding to 
DQ2.5, as described below. Several early DQ2.5 peptide binding studies identified 
five major peptide binding pockets in positions P1, P4, P6, P8 and P9, displaying a 
preference for negative charges in position P4, P6 and P7 of the peptide114-117. The 
molecular basis for this negative preference was largely solved by x-ray crystal 
structure analysis of DQ2.5118. This revealed that lysine in position 71 creates a 
positive region in the groove accommodating position P4, P6 and P7 of the peptide. 
The structure analysis and later reports also revealed a unique ability of DQ2.5 to 
accommodate numerous proline residues without loss of binding affinity119. One 
relatively unique feature of DQ2.5 concerns the accommodation of proline in position 
P1 without energetic penalty120. This is likely due to a deletion of residue 53 in 
DQ2.5, which is normally part of the conserved hydrogen bond network between the 
MHC and peptide backbone. Interestingly, the presence of proline in position P1 of 
gluten antigenic epitopes is a common feature121-123. However, DQ2.5 shares many of 
the above mentioned features with the non-celiac associated DQ2.2 allele. These 
molecules have a virtually identical -chain, but have slightly different -chains 
diverging by only ten amino acids in the membrane distal region124. This is 
demonstrated by their highly similar peptide binding motifs116,125, and further 
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supported by their similar ability to activate gluten specific T cells, though with less 
efficiency in the case of DQ2.212,119. This disparate disease association has remained 
an enigma, though theories have been postulated. One theory concerns the slightly 
inferior gluten presentation by DQ2.2 resulting in an unattainable threshold of T-cell 
activation12,119. One proposed reason for the inferior presentation is a possible lower 
tolerance for accommodating proline in position P3 of the peptide for DQ2.212. 
However, conflicting results oppose this latter theory119. 
 
Pathogenesis of celiac disease 
The celiac lesion is associated with an abnormal influx of lymphocytes to the lamina 
propria and epithelium in response to ingested gluten. The lamina propria 
lymphocytes are dominated by CD4+ T cells that specifically recognize gluten 
peptides presented by DQ2.5/DQ8 expressing APCs126,127. The gluten peptides 
presented by the APC have undergone TG2 mediated deamidation, causing higher 
HLA binding affinity and drastically increases the level of T cell activation122,128,129. 
Upon activation, the T cells secrete large amounts of cytokines dominated by the pro-
inflammatory cytokine IFN-130. 
 
Another aspect of the celiac lesion is the flattening of the mucosa. This is probably the 
result of enterocyte killing by the CD associated infiltrated intraepithelial 
lymphocytes (IELs). This is proposed to be orchestrated by the high amounts of IL-15 
associated with CD131,132. The presentation of -gliadin peptide p123-132 by HLA-A2 
expressing enterocytes has recently been reported to activate gluten specific CD8+ 
IELs, causing up-regulation of IFN-, granzyme and FASL, and subsequent 
enterocyte apoptosis133,134. The presence of IL-15 is suggested to promote this 
cytotoxic effect by lowering the TCR activation threshold through NKG2D up-
regulating, which acts like a co-receptor for the TCR135. Interestingly, IL-15 
production in active CD has been reported to be inducible by -gliadin peptide p31-
43136. This peptide, via IL-15, appears to cause not only an up-regulation of the 
activating natural killer receptor NKG2D on the IELs, but also its ligand, MICA, on 
the enterocyte137. The interaction between these molecules is suggested to provide a 
TCR independent mechanism of inducing epithelial apoptosis135. A third mechanism 
of enterocyte killing may be mediated by another NK receptor, the CD94-NKG2C 
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expressed by the IEL138. This receptor interacts with the stress induced molecule 
HLA-E on the enterocyte, thus causing TCR independent apoptosis, cytokine 
secretion and extensive IEL proliferation. Interestingly, HLA-E expression is induced 
by IFN-139. This cytokine is produced not only by the IELs, but also by the gluten 
reactive CD4+ T cells in the lamina propria, thus providing a possible bridging of the 
innate and adaptive immune response of CD. 
 
Soluble MHC II molecules 
 
The in-depth study of MHC II molecules, involving the intricacies of peptide binding 
and T-cell interaction, is simplified by using MHC II molecules in a cell-free system. 
However, this was originally considered difficult due the requirement of a lipid 
containing environment. This problem was solved in the late 1980’s by treating 
isolated MHC II molecules with papain which cleaved off the hydrophobic 
transmembrane (TM) region140. The disadvantages of this method included non-
specific papain cleavage and a lacking option of modifying the MHC II molecule. 
This was solved a few years later by transfecting cells with modified cDNA from 
MHC II, thus allowing for molecular tailoring. The first reported recombinant 
molecules were still initially membrane bound, where the TM region was replaced by 
a cleavable GPI-linker141. Stern et al omitted the TM region altogether in his insect 
cell produced soluble HLA-DR1 molecules142. The truncation of other MHC II 
molecules were, however, relatively unstable due to the lack of bound peptide, as the 
removal of the TM excluded the molecules from the normal antigen processing 
pathway. This was solved by covalently linking a peptide to the -chain that stabilized 
the binding-groove143. A thrombin site was included in the linker, permitting the 
subsequent peptide release. A subset of MHC II molecules, however, did not 
assemble properly in the absence of the TM region. To resolve this issue a leucine 
zipper dimerization motif was added to mimic the TM domain, which facilitated the 
MHC II folding144. The combining of the above techniques allowed for the expression 
of numerous MHC II molecules, including DQ2.5145. The versatility of the molecules 
were further increased by performing peptide exchange on a thrombin cleaved MHC 
II-peptide construct, thus enabling the production of numerous molecules from a 
single MHC-peptide complex, as reported by Day et al146.  
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 Both eukaryotic, and prokaryotic expression systems have been used for soluble 
recombinant MHC II production142,144,147. A common eukaryotic production system 
utilizes insect cells, which produces pre-folded molecules with post-translational 
modifications like glycosylation. Prokaryotic production systems, on the other hand, 
are easy to handle and rapidly produce vast amounts of protein. However, the required 
in vitro folding of the molecules has proven difficult and has to be tailored for each 
molecule. Also, the lacking of post-translational glycosylation in prokaryotes may 
pose problems, though functional molecules have been produced147,148. 
 
The applications of soluble MHC II molecules are numerous and their 
implementations have been critical in the elucidation of the mechanisms behind 
various HLA related immune processes. In terms of celiac disease, soluble 
recombinant DQ2.5 and DQ8 molecules tethered with a gluten peptide were used to 
solve their x-ray crystal structures, which allowed predictions as to why these HLA 
alleles preferentially bind TG2-treated gluten118,149. Soluble molecules have also been 
implemented in the designing of peptide blockers150,151 (Juse et al, unpublished 
material) and in the successful targeting of CD specific CD4+ T cells by using 
tetramers of soluble DQ2.5 molecules with linked gluten peptides145.  
 
MHC tetramer technology 
 
The detection and analysis of the antigen specific T cells was revolutionized with the 
introduction of MHC tetramers152. This flow cytometry-based technology utilized 
tetramers consisting of four MHC I-peptide complexes multimerized on a 
fluorescently labelled streptavidin molecule, to identify antigen specific CD8+ T cells. 
The tetramer technology was later applied to MHC II molecules and the identification 
of antigen specific CD4+ T cells. However, due to the combined low frequency of 
disease related CD4+ T cells and the low TCR-MHC II affinity, these tetramers are 
associated with low success rates153-155. The key to the tetramer technology is the 
overcoming of the inherent low affinity of a single MHC-TCR interaction by creating 
an MHC multimer, which increases the avidity of the interaction156,157. The molecules 
are therefore engineered to have a tail-linked biotin that associates with one of the 
25 
four biotin binding pockets of streptavidin. This ensures the binding groove exposure 
of all MHC molecules, though the rigidity and structure of streptavidin prevents more 
than three simultaneous TCR interaction points158. Since the introduction of the 
tetramer, additional multimers, such as pentamer and octamers have also been created 
with the purpose of increasing the avidity159,160. In celiac disease, the known identity 
of several gluten T-cell epitopes facilitated the successful production of MHC II 
tetramers that recognized disease relevant CD4+ T-cell lines and clones145. 
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AIMS OF THE STUDY 
 
This thesis focuses on two main aspects; 1) the molecular mechanism behind the 
celiac disease association of DQ2.5, and 2) the detection of gluten specific T cells in 
peripheral blood, both aspects in which include the extensive use of soluble 
recombinant HLA II molecules. Firstly, DQ2.5 is associated not only with celiac 
disease, but also to various other autoimmune diseases. We sought to find the 
molecular basis for this extensive association by studying aspects of peptide binding 
and presentation to DQ2.5, and comparing this with the highly similar, but non-
disease associated DQ2.2. Secondly, we aimed to use HLA II tetramers to detect and 
characterize gluten specific T cells in peripheral blood of treated CD patients after a 
short gluten challenge.  
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SUMMARIES OF THE INDIVIDUAL PAPERS 
 
Paper I 
This study investigates the conspicuous finding that peptide elution from DQ2.5-
expressing B-LCL is associated with high levels of two cohorts of invariant chain 
fragments. The cohorts consist of the established CLIP1, but also an alternate CLIP2, 
with a slightly shifted binding frame as determined in this study. By using soluble 
recombinant HLA II molecules in dissociation studies, we determined that the CLIP 
peptides had relatively high intrinsic stability for DQ2.5, with a dissociation rate two 
fold slower than CLIP1 from DR3. Interestingly, dissociation in the presence of DM 
revealed a mere 16-28 fold increase in dissociation for CLIP1 and CLIP2 from 
DQ2.5, respectively, compared to the ~250 fold increase as seen for CLIP1-DR3. An 
additional set of peptides of varying stability for DQ2.5 was tested and the DM effect 
in relation to intrinsic peptide stability was compared with other HLA alleles from 
previous studies. This comparison revealed a clear inefficiency of DM for DQ2.5. The 
abnormal DM interaction was also observed in studies involving B-LCLs where the 
absence of DM neither changed the conformation, cell surface expression, nor the 
high CLIP association of DQ2.5. A possible contributing factor to the observed high 
CLIP content on DQ2.5 was found to be the competitive inhibition of DM by the co-
expressed DR3.  
 
Paper II 
This paper aims to describe the differential association of DQ2.5 and DQ2.2 with 
celiac disease. The study builds on paper I, comparing the CLIP1 content in peptide 
elutions from DQ2.5 expressing cells with that of the non-celiac associated, but highly 
homologous DQ2.2. Conspicuously, DQ2.2 had a very low CLIP1 phenotype. 
Dissociation studies using soluble DQ2.5/2-CLIP1 complexes revealed this low 
CLIP1 phenotype was not due to an increased DM efficiency, but rather a drastically 
lower intrinsic stability of CLIP1 for DQ2.2. Upon further dissociation studies with 
mutant DQ2 molecules, we determined that DQ22, out of the total ten polymorphic 
residues, was the cause of the differential stability for CLIP1. This polymorphism 
determines the presence (DQ2.5) or absence (DQ2.2) of a hydrogen bond to the 
peptide backbone, which therefore affects the binding of all peptides to DQ2. The 
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functional relevance of this finding was determined via a functional off-rate study, 
where peptide-pulsed APCs were incubated in the absence of peptides for various 
time points prior to T cell addition. The results showed that DQ2.5-expressing APCs 
retained the ability to activate T cells much longer than the DQ2.2 counterpart. This 
increases the opportunity of T cell/antigen encounter, thus influencing the initiation of 
the anti-gluten T-cell response. The findings in this paper display the potential 
importance of these polymorphic MHC to peptide backbone hydrogen bonds in 
peptide binding. Furthermore, this presents a possible link for the extensive 
association of DQ2.5 to several autoimmune diseases, as the generally low affinity 
auto-antigens will gain kinetic stability and thereby open for T-cell response 
initiation.  
 
Paper III 
The goal of the study was to investigate whether or not gluten specific T cells were 
detectable in peripheral blood after a gluten challenge of treated CD patients. 
Following a three day gluten challenge (160 g white bread) on ten DQ2.5+ celiac 
disease patients and six controls who were all previously on a gluten free diet, we 
were, by using HLA II peptide tetramers, able to detect DQ2--I and DQ2--II gliadin 
specific T cells in the celiac disease patients, but not in the controls. The findings 
were confirmed by quantifying IFN- in ELISPOT assays. The identified T cells were 
phenotypically characterized and found to express the gut homing integrin 7, which 
concurs with the expected intestinal destination. The cells were otherwise expressing 
a heterogeneous set of markers. The results of the study opens for the use of MHC 
class II tetramers as a diagnostic tool for diseases where the antigen and MHC 
restriction element is known. 
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METHODOLOGICAL CONSIDERATIONS 
Soluble HLA II-peptide molecules 
 
The water soluble HLA II molecules used in this work were made up of various gene 
components combined into expression plasmids, as previously described145. The 
membrane distal part of the HLA - and -chains had C-terminally linked 
complementary Fos/Jun leucine zipper dimerization motifs. The -chain was further 
modified by the C-terminal addition of a biotinylation sequence, which allows the 
attachment of a single biotin molecule by means of biotin ligase (BirA) from E.coli. 
Additionally, a peptide was covalently attached via a thrombin site containing linker 
at the N-terminus of the -chain (Fig. 4a). The gene-expression plasmids were 
transfected into ExpresSF+ insect cells using a baculovirus transfection system and 
proteins were expressed in a serum free medium to avoid contaminating serum 
proteins. The proteins were isolated and purified by immunoprecipitation. In the case 
of tetrameric complexes, the soluble HLA II-peptide molecules were first biotinylated 
by the BirA enzyme and then allowed to multimerize on a streptavidin backbone via 
the four biotin specific binding sites (Fig. 4b). 
 
 
a                   b 
Figure 4  Schematic presentation of a single and tetrameric soluble HLA II–peptide molecule. a.) 
The membrane distal part of the -chain (red) and -chain (blue) is dimerized via a leucine zipper (in 
black). The peptide (in green) is covalently attached to the -chain via a linker containing a thrombin 
cleavage site (scissors). A BirA site (in yellow) is included at the end of the -chain for subsequent 
biotinylation and tetramer assembly. b.) The biotinylated (marked “B”) MHC II – peptide molecule 
multimerized on a streptavidin molecule (in brown) with fluorescent dye (red star). 
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HLA II-peptide interaction assays 
Soluble HLA II-peptide dissociation assay 
This dissociation assay uses soluble HLA II-peptide molecules to measure the kinetic 
stability of a bound peptide. In short, the molecules were thrombin cleaved to allow 
for peptide release and incubated for various timepoints before separating the bound 
from the released peptides. The still-bound peptides were eluted in the presence of an 
internal standard of known quantity and analyzed on a MALDI-TOF MS instrument. 
The relative quantity of remaining peptide in each sample was determined by 
comparing the ionization peak intensity of the peptide with that of the internal 
standard, and the results were fitted to a single exponential decay curve. This system 
has the obvious advantage of eliminating the peptide loading step. The permanent 
close proximity of the peptide to the groove would limit the possible intermediate 
binding of peptides, as seen for double exponential decay curves. Also, with regards 
to CLIP, the tethering of CLIP to the MHC II is likely the most physiologically 
relevant manner to measure the kinetic stability as it simulates the manner in which Ii 
assembles to MHC II in the ER. Notably, the loading of CLIP onto detergent 
solubilized DQ2.5 for off-rate measurements was unsuccessful (data not shown). 
 
Another advantage of using water soluble truncated molecules over detergent 
solubilized full length molecules in dissociation studies is the reported increase in 
peptide dissociation due to the presence of detergent161. Additionally, the detergent 
effect was proposed to be allele dependent, which would complicate the comparison 
of dissociation rates between alleles. Notably, in the case of DQ2.5, the -I-gliadin 
peptide showed a comparable dissociation rate in both systems (detergent solubilized 
DQ2.5 off-rate shown in120). 
 
Fluid-phase peptide binding/exchange assay 
To assess the binding efficiency of peptides to HLA II, we used a traditional 
inhibition assay as previously described162. This assay measures the ability of a 
peptide to inhibit, or out-compete, the binding of a radioactively labelled indicator 
peptide, thus giving an indication of the binding capacity. This assay was applied in 
the CLIP2 binding frame determination utilizing a combination of N- and C-terminal 
peptide truncations, together with a lysine scan, which takes advantage of the 
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molecule’s ability to accommodate a lysine residue in position 5 of the peptide, but 
not in positions 4 and 6.  
 
A similar assay was applied to determine the differential DM efficiency on DR3 and 
DQ2.5 using water soluble HLA II-CLIP complexes. This assay measured the ability 
of a titrated amount of DM to exchange CLIP1 for a high affinity radioactively 
labelled indicator peptide. In addition, the ability of DR3 to competitively inhibit DM-
DQ2.5 interaction was assessed by utilizing this assay, but in this case a titrating 
amount of un-cleaved DR3-CLIP molecules was added. The assay with reversed roles 
of the molecules was also completed. This assay attempts to mimic the in vivo 
situation where DR3 is present in ten fold excess140. However, the inability to displace 
the peptide from the HLA II molecule may have an unknown effect on the DM-HLA 
II interaction. 
 
Solid-phase peptide exchange assay 
The level of peptide exchange was also assayed in an antibody based catch assay 
modified from Stepniak et al163. This assay was used to explore the effect of DM on 
DQ2.5 compared to that of DR3 in cells. Lysates of hemizygous DQ2.5/DR3 Epstein 
Barr virus (EBV) transformed B lymphoblastoid cell lines (B-LCL) either expressing 
or not expressing DM, was added to wells with DQ-specific or DR-specific 
antibodies. Biotinylated high affinity peptides were added and following incubation, 
the amount of exchanged peptide was measured by time-resolved fluorometry using 
europium-labeled streptavidin. The intra-allelic differences in spontaneous exchange 
with biotinylated peptides were used as a measure of DM effect, as DM favorably 
exchanges CLIP for higher affinity peptides. This assay is quick and requires little 
work; however the quantity of the bound HLA II is unknown, although the intra-
allelic relative quantity was measured by using a secondary biotinylated anti-DQ or -
DR antibody. However, since this is only a relative measure of HLA II quantity, inter-
allelic comparisons cannot be performed with this assay. 
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CLIP quantification 
 
 
The CLIP phenotype assessment was completed in EBV transformed B-LCLs. 
However, this analysis could have benefited from being completed in dendritic cells, 
because of the important role of DCs in naïve T-cell activation and positive/negative 
thymic selection. However, due to the difficulties associated with culturing of these 
cells, the readily available BLCLs were used in this work. 
 
B-LCL peptide elution and MS quantification of CLIP 
The immunoprecipitation of HLA II molecules from B-LCLs were completed 
essentially as described114. The HLA II molecules were acid eluted and peptides were 
isolated by use of a size exclusion filter. The CLIP peptides were identified by 
MS/MS analysis. To assess the CLIP1 phenotype of APCs, peptides were analyzed on 
the MALDI-TOF MS. One limitation of this method was the inability to detect CLIP2 
due to the low ionization of these peptides. However, the high ionizing efficiency of 
CLIP1 allowed for a rough comparison of relative CLIP1quantity in cells by 
comparing their peak intensity with that of the other endogenous peptides. To 
accurately quantify the CLIP1 and CLIP2 peptides, we labeled the eluted peptides and 
CLIP indicator peptides with heavy and light versions of isotope-coded protein labels 
(ICPL), followed by LC-MS analysis. The labeling allowed us to separate the eluted 
peptides from the indicator peptides on the MS spectrum without affecting the LC 
retention time or the ionization efficiency of the peptides. Quantification was 
completed by peak intensity comparisons of the eluted peptides with the indicator 
peptides of known quantity. One problem that emerged with the quantification was 
the occurrence of oxidated form of the peptides. However, as this appeared to be the 
result of the centrifugation and lyophilization process, we assessed that the level of 
oxidation would be similar for eluted peptides and indicator peptides. 
 
Flow cytometric assessment of CLIP1 phenotype 
The assessment of the CLIP phenotype through flow cytometry analysis is a time 
efficient and easy way to assess the level of CLIP expression in reference to the level 
of DQ expression on the cell surface. However, there are several disadvantages of this 
method. The employed CLIP antibody (cerCLIP1.1) recognizes CLIP peptides bound 
33 
to all alleles expressed by the APC. In addition, the antibody only recognizes a limited 
number of the CLIP1 variants, and no CLIP2 variants. In the case of the B-LCL 
transfectants in paper II there were no interfering DR alleles, thus allowing for 
differential surface CLIP amount assessment. The latter issue, however, could have an 
impact on the CLIP1 phenotype assessment if different alleles have variable 
preference for CLIP1 variants. However, in our case, the MS analysis supported the 
results obtained by flow cytometry. 
 
T cells  
Tetramer staining of T cells 
The tetramers used in this study consisted of streptavidin conjugated sDQ2.5--I 
gliadin or sDQ2.5--II gliadin complexes. In addition, a negative control tetramer was 
also used where DQ2.5 was tethered to a self-peptide (a peptide originating from an 
HLA I molecule found to be a dominating self-ligand for DQ2.5115,117). CD4+ T cells 
isolated from peripheral blood were co-stained with tetramers and conjugated 
monoclonal antibodies specific for various surface markers, and subsequently 
analyzed by flow cytometry. The specificity of the tetramers was also determined by 
staining a T cell specific for the -I gliadin epitope with a tetramer presenting the -II 
gliadin epitope, and vice versa. This test displayed a very low cross-reactivity and 
background staining (Fig. 5).  
                 
Figure 5  Specificity-testing of tetramers. Two T-cell clones were tested for 
cross-reactivity. The T-cell clones were only stained with the tetramer that 
contained their specific epitope. The control tetramer showed background 
staining. This figure is taken from article III (Supplementary Information, Fig. 
6). 
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The high specificity of these tools reduces the likelihood of obtaining false positives, 
which shows their applicability in the identification of antigen specific T cells of low 
frequency. 
 
T-cell proliferation assays 
The T-cell assays in this work measured the 3H-thymidine incorporation of 
proliferating T cells as a result of TCR recognition of APC-presented gluten antigen. 
The APCs used were -irradiated B-LCLs either 1) DR3/DQ2.5 homozygous, or 2) 
DQ-/DR-deleted cells that were retrovirally transfected with wild type or mutated 
DQ2.2/DQ2.5 full length molecules. The T-cell clones were derived from various 
gluten reactive T cells isolated from DQ2.5+ celiac disease patients. We performed 
two types of assays: 1) The standard assay, with peptide incubation of APC followed 
by direct addition of T cells119, and 2) the functional off-rate assay, where the peptide-
pulsed APC was incubated for various time points in the absence of peptide prior to 
T-cell addition70.  
 
For certain gluten peptides, the traditional T-cell assay did not reveal a difference 
between the T-cell activation capability of DQ2.2- and DQ2.5-expressing APCs. In 
contrast, the functional off-rate assay displayed dramatic time-dependent differences 
in the T-cell activation capability of the same APCs. These differences reflect the 
kinetic stability variations of the peptide-HLA complexes, indicating that this assay is 
a better measure of the physiological relevance of the antigen. 
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DISCUSSION 
Soluble recombinant HLA II molecules as tools in disease analysis 
 
HLA II molecules are major players of the immune system through their presentation 
of endogenous and exogenous peptides on APCs. The presentation of processed 
fragments of pathogens alerts the immune system of its presence, thus allowing for a 
powerful response by pathogen specific T cells. Autoimmune diseases display a 
similar immune reaction, as most of these are associated with peptide-presenting HLA 
molecules85. This association implicates two interrelated main aspects of the reaction: 
1) The uptake, processing and presentation of the antigen on HLA molecules, and 2) 
the subsequent interaction of T cells specific for the HLA-antigen complex. A third 
aspect of HLA involvement is the role in thymic selection of T cells, which upon 
faulty regulation may yield an increase in autoimmune T cells.  
 
Water soluble recombinant MHC II molecules are constructed in a variety of ways, 
but common to all is the removal of the hydrophobic transmembrane region. One 
major advantage of these molecules is the detergent independence, which allows for 
easier handling and a wider specter of applications. These include the determination 
of peptide affinity for HLA molecules via association and dissociation studies, and 
also the significance of polymorphic residues for this affinity through mutational 
studies. In addition, the elucidation of the mechanism behind DM’s peptide editing 
function, and the proposed DM interaction site on HLA were largely dependent on 
these tools. The solving of numerous crystal structures were also facilitated by these 
molecules, which subsequently allowed for modeling of the TCR-MHC interaction. 
Furthermore, the use of HLA tetramers allows for not only the identification and 
quantification of disease specific T cells, but also the isolation of these cells to further 
characterize their effector functions.  
 
The ancestral HLA haplotype 8.1, comprising of the HLA-A1, -B8, -DR3, and  
-DQ2.5 alleles, is associated with more than 30 autoimmune diseases and is therefore 
termed the “autoimmune haplotype”164,165. Notably, for several of the diseases the 
major HLA association have been mapped to the DR3-DQ2 interval166,167. In the case 
of CD, the role of DQ2.5 is largely defined by its unique ability to bind and present 
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proline rich deamidated gluten peptides to gluten specific CD4+ T cells. However, the 
extensive association with autoimmune diseases suggests that this molecule may have 
unique properties that go beyond its ability to bind proline rich sequences. Paper I and 
II attempts to unravel this uniqueness through extensive use of recombinant soluble 
MHC II molecules. 
 
DQ2.5 and DM inefficiency 
 
A unique property of DQ2.5 is the previously reported high abundance of two cohorts 
of CLIP peptides among natural ligands eluted from APC-isolated DQ2.5 
molecules115,117. A high level of CLIP-expressing HLA II on APCs is not a common 
trait, and has been associated with loss of DM expression168. This was addressed in 
paper I, by developing a peptide dissociation assay using soluble recombinant DR3 
and DQ2.5 molecules tethered to a peptide by a cleavable linker. This method gives 
~100% loading of CLIP and thus simulates the Ii loading in the ER. The dissociation 
assay was completed in the presence or absence of DM, which allowed us to 
determine that the underlying mechanism for the CLIP-high phenotype of DQ2.5 was 
indeed due to DM inefficiency, combined with a relatively high kinetic stability of 
CLIP. By using the same molecules in a DM competitive inhibition assay, we also 
found that DR3 was able to out-compete DQ2.5 for DM interaction, which would 
further diminish the effects of DM. However, the mechanism for the low DM 
interaction was not determined during this work. On the other hand, it is interesting to 
speculate whether or not the naturally occurring deletion of residue 53 in DQ2.5 may 
be involved. The proposed DM induced conformational change in HLA II is 
suggested to be mediated by a “lever action” through hydrophobic interactions 
between the protruding phenylalanine in position 51 (51F) and corresponding 
residue in DM46,51. This may move the extended 51-53 strand, thus destabilizing the 
peptide by breaking the associated hydrogen bonds. The possible effects of the 53 
deletion can be illustrated with crystal structures of DR3-CLIP6 and DQ2.5--I 
gliadin118, by comparing their presumed DM interacting site (Fig. 6) (Notably, the 
proposed DM interaction site was determined by biochemical studies using the HLA-
DR1 allele47,48). In contrast to the 53-sufficient DR3, the 53 deletion in DQ2.5 
shortens the extended strand, thus leaving the hydrophobic 51F residue “hidden” 
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behind the hydrophilic arginine in position 50 (50R). This hydrophobic to 
hydrophilic surface change could have an impact on both the association to and the 
“lever action” of DM on DQ2.5.   
 
 
                DR3-CLIP                          DQ2.5--I gliadin 
Figure 6  Proposed DM interacting residue 51F is exposed for DR3, but hidden for DQ2.5. The 
alpha-chain of DR3 and DQ2.5 (in blue) with the N-terminal end of the CLIP (DR3) and -I gliadin 
(DQ2.5) peptide (in turquoise). Position P1 of the peptide is in red. Figures were generated using 
PyMol (DeLano Scientific LLC). 
 
To further investigate the potential role of the 53 deletion on DM efficiency, 
recombinant soluble DQ2.5 molecules that contained insertions of either arginine or 
glycine in this position were constructed and expressed. However, the peptide 
dissociation from these molecules was extremely quick, indicating that the insertion 
may have altered the binding groove conformation (Fallang et al, unpublished 
results). Further studies must therefore be completed to investigate the role of the 53 
deletion, or to pinpoint other causal residue(s). 
 
The low DM efficiency of DQ2.5 has potential implications for peptide exchange and 
antigen presentation in the periphery. Moreover, it may affect thymic selection and T-
cell tolerance. This is supported by studies done with mice either lacking DM, or 
expressing a single MHC II-peptide complex. These studies reported changes in the 
CD4+ T-cell population, including a reduction in numbers and diversity, a more 
promiscuous ligand recognition, and increased occurrence of autoreactive cells55-57,169-
171. These effects were suggested to be the result of inefficient positive and negative 
thymic selection. It is therefore tempting to speculate that the DM insensitivity and 
CLIP abundance found with DQ2.5 can lead to a limited CD4+ T-cell repertoire 
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containing promiscuous and autoreactive T cells, thus offering a possible explanation 
to the disease association of the DR3/DQ2 haplotype. 
 
Contrary to our findings, there have been reports that MHC II displaying low CLIP 
affinity is associated with autoimmune diseases, as reviewed by Busch et al172. One 
example is the positive or negative association of various DR4 alleles with 
rheumatoid arthritis, which correlates with their CLIP affinity173. However, the same 
study reports exceptions to this linkage. Busch et al therefore proposes that the 
mechanism for disease association differs between alleles of high or low CLIP 
affinity. This is further supported by dissociation studies from paper II, which show 
that the non-CD associated DQ2.2 has low CLIP kinetic stability.  
 
Differential association of DQ2.5 and DQ2.2 with celiac disease – 
Molecular aspects 
 
The importance of HLA polymorphisms with regards to disease association was 
originally assessed in the one-dimensional context of linear sequences, thus limiting 
the accuracy of the predicted effect. However, the emergence of crystal structures of 
soluble recombinant HLA molecules with tethered peptides allowed for more refined 
predictions1. These three-dimensional models display whether or not polymorphisms 
affect the TCR docking and/or the peptide binding to HLA by altering the hydrogen 
bonding or binding groove conformation. The predicted involvement of polymorphic 
residues in peptide binding is normally based on “pocket-anchor” interactions, 
involving peptide side chains and polymorphic HLA residues86. 
 
Of two variants of DQ2, DQ2.5 shows high association with celiac disease, while the 
highly similar variant DQ2.2 does not. As their peptide binding properties are highly 
similar and they both have the ability to activate gluten specific T cells, the 
differential association has remained an enigma. Previous structural analyses of 
DQ2.5 have focused on the uniqueness of the lysine in position 71 of the -chain 
(71K)86,118. This positively charged residue mediates a preference for negative 
charges in positions P4, P6 and P7 of the peptide, which is common in TG2-modified 
gliadin epitopes. However, since DQ2.2 has virtually the same -chain as DQ2.5 
(DQB1*0201 and DQB1*0202 differ only at residue 135 in the membrane proximal 
39 
domain), the 71K residue does not explain their differential CD association. 
Structural analysis of DQ2.5 reveals that the two molecules differ in their -chains by 
ten polymorphic residues in the ligand binding domain (Fig. 7). Six of these residues 
are located in the proposed DM interaction site, thus making a differential DM 
peptide editing a possible candidate. This speculation was initially supported by 
findings in paper II showing that the CLIP amount was very low among natural 
ligands eluted from DQ2.2 isolated from B-LCLs. However, dissociation experiments 
using soluble DQ2.5-CLIP molecules with the six polymorphic residues changed to 
the corresponding residues of DQ2.2, did not significantly alter the DM effect. The 
theory was further weakened by the subsequent observation that the dissociation rate 
of CLIP from DQ2.2 was thirty-six folds faster than for DQ2.5, and that they 
displayed a similarly low effect of DM. Interestingly, both molecules have the 53 
deletion, which underscores the potential importance of this deletion in the observed 
low DM interaction of both molecules. 
          
-chain
-chain
R49H
Q31E
G37E
L48F
C44KV47L
Q50R
F51L
S72I
Y22F
 
Figure 7. DQ2.5--I gliadin complex displaying polymorphic amino acid residues of DQ2.5 
and DQ2.2. The polymorphic residues are displayed in red lettering. The figure also depicts 
the extensive hydrogen bonding between the HLA and peptide. Figure modified from118 
 
The lacking role of DM led us to analyze the remaining four polymorphisms. The 
crystal structure revealed an obvious candidate in the tyrosine in position 22 (22Y) 
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due to its involvement in hydrogen bonding, via a water molecule, to the peptide 
backbone118 (Fig. 7). DQ2.2 accommodates a phenylalanine in this position, which 
lacks the hydroxyl required for this hydrogen bond network. To study this 
polymorphism, we performed dissociation assays using soluble CLIP-linked DQ2.2 
and DQ2.5 molecules containing switched residues in 22. Strikingly, the switching 
of 22 caused a reversal of CLIP kinetic stability, thus displaying the importance of 
this hydrogen bond. The same assay using constructs linked to a gliadin peptide 
mirrored the result of CLIP, thus connecting the finding to celiac disease. The 
observations were further confirmed by transfecting 22 mutant DQ2.5 and DQ2.2 
full length molecules into DQ- and DR-devoid B-LCLs, which displayed a reversal of 
the DQ2.5 and DQ2.2 CLIP phenotype.  
 
The hydrogen bonding between polymorphic MHC residues and peptide backbone, 
though prevalent in both DQ and DR alleles, has been given little attention with 
regards to the influence on peptide binding. One reason for the neglect may be their 
frequent bonding via water molecules that are not always visible due to the 
requirement of high resolution crystal structures. Due to the peptide backbone 
involvement, this hydrogen bond will have a universal effect on all ligands 
irrespective of sequence. The impact on the peptide affinity is potentially huge and the 
inclusion of these bonds may therefore prove crucial when predicting the effects of 
polymorphisms. 
 
Differential association of DQ2.5 and DQ2.2 with celiac disease – 
Physiological aspects 
 
In terms of celiac disease, the functional relevance of the differential peptide kinetic 
stability observed with the 22 polymorphism is likely related to the ability of the 
dendritic cell to retain antigen for prolonged presentation. DCs that endocytose 
antigen in the tissue travel to lymph nodes for antigen presentation to T cells. This 
potentially long transition time presents a requirement for sufficient peptide affinity as 
suggested by Lanzavecchia et al70. The same author showed that immunogenic 
peptides are functionally bound irreversibly in that the half life of the complex is 
higher than the rate of MHC II turnover. To assess the proposed functional effect of 
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the 22 polymorphism on the two DQ2 molecules, we adopted the functional off-rate 
assay done by Lanzavecchia et al70. This assay measures the effect of peptide 
dissociation on the ability of the APC to present antigen to T cells, thus mimicking the 
transit time of the DC traveling from tissue to lymph node. In order to directly relate 
our findings to celiac disease, we pulsed APCs with gluten peptides and measured 
their ability to activate gluten specific T cells. As expected, DQ2.5 displayed an 
efficient presentation of gliadin peptides over time, while the T-cell stimulatory 
capacity of DQ2.2 diminished rapidly for all gluten peptides tested. In addition, a 
reversal of the stimulatory capacity was observed when using 22-switched DQ2.5 
and DQ2.2 expressing transfectants as APCs, thus verifying the causative role of 22. 
This finding presents evidende that the differential association of the two DQ2 
variants with celiac disease may be due to differences in their inherent kinetic stability 
of gluten peptides. Credence to this notion has been obtained in an in vivo study in 
mice of MHC I and CD8+ T cells174. In this study, Henrickson et al demonstrated that 
a small difference in peptide kinetic stability (t½ 2.4 h vs. 6 h) of two peptides, 
differing only at the P9 residue, translated into an enormous (30,000 fold) difference 
in antigenicity in the lymph nodes. This was assayed by injection of CFSE labeled T 
cells into mice 18 hours after footpath injection of DCs pulsed with either of the two 
peptides. The dramatic observed effect was ascribed to changes in the dynamic 
interaction between the naïve T cell and DCs, which was found crucial for the 
transition of the T cell from a naïve state to a state of activation and subsequent 
proliferation. These observations underscore the relevance of our reported peptide 
stability differences between the DQ2 variants in terms of celiac disease association. 
It is plausible that the transition time associated with DC migration to lymph nodes, 
combined with the disparate kinetic stabilities of gluten peptides for DQ2.5 and 
DQ2.2, may result in antigen density differences that would ultimately affect the T 
cell-DC interaction dynamics and subsequent naïve T cell activation. However, once 
the anti-gluten T-cell response is initiated, the activation of the effector T cells in the 
lamina propria would not be affect by these kinetic stability differences. The anti-
gluten immune response of the few DQ2.2+ and the DQ2.5+ CD patients would 
therefore be indistinguishable. 
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Our work, and the work by Lanzavecchia70, Henrickson174 and others, imply that in 
the quest for disease precipitating antigens, the importance of kinetic stability for the 
MHC must compliment the specificity of the T-cell epitope in order to find the grail. 
  
Detection of disease specific T cells in peripheral blood of celiac 
disease patients 
 
Soluble MHC I molecules in fluorescently labeled tetramers have been extensively 
utilized as tools to identify and characterize disease specific T cells. However, the use 
of soluble MHC II molecules have proven difficult due to the combined low 
frequency of disease related CD4+ T cells and the low TCR-MHC II affinity154,155. 
This appeared to be the case for celiac disease as well, as initial efforts using 
tetramers to detect gluten specific T cells in the tissue of treated or untreated celiac 
disease patients were unsuccessful (Quarsten et al, unpublished results). In paper III, 
however, based on a study by Anderson et al175, we were able to detect gluten-specific 
CD4+ T cells in peripheral blood with DQ2.5--I/-II gliadin tetramers after doing a 
short gluten challenge of treated celiac patients. By co-staining with specific 
antibodies and the tetramers, we were also able to phenotypically characterize these 
IFN- producing T cells, which revealed the gut-homing associated 7 integrin as a 
common marker. The imprinting of gut-homing on T cells has been contributed to 
DCs located in gut-associated secondary lymphoid organs176,177. Therefore, the 
identified T cells likely represent activated naïve or central memory T cells in transit 
from secondary lymph nodes to the small intestinal lamina propria. Characterization 
of other phenotypic markers revealed a great heterogeneity. This may represent the 
various states of differentiation of the T cells following the previous antigen 
stimulation, as suggested by Roman et al178.  
 
The diagnosis of celiac disease is based on a combination of several techniques. 
However, the only accepted method is biopsy analysis of the small intestine, where 
the level of villous atrophy, crypt hyperplasia and IEL infiltration determines disease 
severity/presence, as graded by the Marsh scoring system179. However, this analysis 
has certain pitfalls. The affected mucosa of a celiac patient is not always significantly 
altered, and the potential patchiness of the celiac lesion may lead to difficulties 
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making the correct diagnosis179. The serological detection of IgA antibodies towards 
deamidated gluten and TG2 is another tool for CD diagnosis, which both display 
similarly high sensitivity and specificity for celiac disease180. The presence of anti-
TG2 in celiac patients has been detected even in the absence of significantly altered 
mucosa181, thus revealing the importance of serology. However, these tests are not 
fool proof, as false negative results occur. The known predisposition of celiac patients 
to IgA deficiency further complicates the matter182. There is also a cohort of CD 
patients that are on a gluten free diet without a proper clinical work up. Therefore, 
there are likely healthy individuals among the treated CD patients that could benefit 
from being re-diagnosed. However, the re-diagnosis of such patients requires at least a 
month-long gluten challenge in order for clinical signs to reoccur, presenting the need 
for an improved method. The use of DQ2.5 tetramers, as described in paper III, may 
therefore represent a potential diagnostic tool to distinguish the treated healthy 
individuals from the CD patients. 
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FINAL COMMENTS 
 
The work in this thesis demonstrates that soluble recombinant HLA II molecules can 
be powerful tools in assessing the molecular basis for disease association, and 
potentially also in disease diagnostics. Interestingly, our findings have extended 
implications in the understanding of peptide-HLA interaction. Peptide binding affinity 
for HLA II molecules have been mainly attributed to two established principles 
involving conserved hydrogen bonds and “pocket-anchor” interactions. We show that 
a third principle, involving hydrogen bonds between polymorphic HLA II residues 
and the peptide backbone, is a major determinant of the peptide-HLA II interaction. 
The significance of this bond was exemplified in our work as its presence or absence 
likely plays a role in the observed differential celiac disease association with two DQ2 
alleles, due to peptide kinetic stability differences. The role of such hydrogen bonds 
may also be important in the HLA-association for other diseases, and should be 
investigated. However, in order to ensure the validity of our results, the in vitro 
findings must be transferred to an in vivo situation. This will be our focus in future 
studies. 
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ERRATA 
 
Paper I 
 
In the Results section under the first subhead, In cells, CLIP is released from DR3 
more efficiently than from DQ2, the corrected text in the second half of the first 
paragraph should read as follows: "CLIP was detected in association with both DQ2 
and DR3 molecules at the 8-h postsynthesis time point. In the presence of DM (8.1.6 
cells), the CLIP:DR3 ratio is significantly lower at 8 h of chase (23% of 9.5.3), 
whereas the change in the CLIP:DQ2 ratio is more modest (66% of 9.5.3; Fig. 1B and 
densitometric analysis in C). Thus, DQ2-CLIP complexes appear more resistant than 
DR3-CLIP to DM-mediated peptide exchange. Formally, DM resistance could result 
from a thermodynamic block (reduced DM binding to DQ2-CLIP) or a kinetic block 
(reduced ability of DM to release CLIP from DQ2). The finding that increased DM 
(9.5.3-DM) further reduces DQ2-CLIP levels at 8 h (23% of levels in 9.5.3) suggests 
that the block is thermodynamic. At all levels of DM, CLIP removal is more efficient 
from DR3 than from DQ2 (Figs. 1, B and C)."  
The corrected legend for Fig. 1 should read as follows: "FIGURE 1. The efficiency of 
Ii peptide release from DQ2 is lower than from DR3 and related to the level of HLA-
DM. A, Intracellular DM staining of the indicated cell lines using anti-HLA-DM 
dimer Ab. B, 9.5.3, 8.1.6, and DM transfectant of 9.5.3 (9.5.3-DM) cells were pulsed 
for 1 h with [35S]methionine/cysteine and then chased in label-free medium. Cell 
lysates (3 x 106 cell equivalents/lane) were immunoprecipitated with anti-DQ mAb, 
SPV-L3 (top), or anti-DR mAb, L243 (bottom), at the indicated times (hours) of chase 
and then analyzed by SDS-PAGE. Representative images from one of two 
independent experiments are shown. C, Densitometry analysis calculating ratios of 
CLIP to class II band intensity at 8 h from images shown in B. D, Assessment of cell 
surface CLIP-class II accumulation by FACS analysis. Indicated cell lines (9.5.3: 
DR3, DQ2, DP4, DM-null; 9.22.3: DQ2, DP4, DM+; 3.1.3: DQ1, DP4, DM+; 5.2.4: 
DP4, DM-null) were stained with anti-CLIP (CerCLIP.1; left panel) and anti-DQ 
(SPV-L3; right panel) followed by a secondary Ab (FITC-conjugated goat anti-mouse 
IgG). Control staining (without primary Ab: dotted lines) is comparable on all cell 
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lines and histogram for one representative cell line is shown in each panel. CLIP:DQ 
ratios were calculated as MFICerCLIP – MFIisotype ÷ MFISPVL3 – MFIisotype: CLIP:DQ1 = 
1:75.9; CLIP:DQ2 = 1:11.3; p < 0.04. Representative data from one of more than 
three experiments are shown." 
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